Parameter Without invalidity and/or rheumatic disease (n=23)2 With comorbidities (n=33)2
Group A Group B p value3 Group A Group B p value3
(n=11) (n=12) (n=17) (n=16)
SF-36 transformed scores
Physical components-total 59.3 86.3 0.001 54.3 64.8 0.218
(17.8-98.0) (71.0-95.5) (11.8-95.5) (23.0-93.0)
Physical Function 74.3 91.7 0.031 53.4 70.9 0.085
(10.0-95.0) (80.0-100.0) (0.0-95.0) (20.0-95.0)
Role Physical 52.3 95.8 0.004 53.1 68.8 0.22
(0.0-100.0) (75.0-100.0) (0.0-100.0) (0.0-100.0)
Bodily Pain 66.6 87.5 0.021 67.8 69.3 0.969
(31.0-100.0) (62.0-100.0) (22.0-100.0) (0.0-100.0)
General Health 44 70.2 0.001 45.1 50 0.456
(20.0-97.0) (52.0-87.0) (10.0-87.0) (15.0-77.0)
Mental components - total 66.6 78.4 0.015 75.2 68.5 0.132
(48.6-89.0) (68.4-84.5) (53.3-88.3) (45.5-87.5)
Vitality 61.2 75.4 0.06 62.5 63.7 0.851
30.0-100.0) (60.0-90.0) (30.0-90.0) (5.0-95.0)
Social Function 67.7 64.6 0.439 72.4 68.8 0.285
(60.0-95.0) (60.0-80.0) (60.0-90.0) (60.0-95.0)
Role Emotional 70.4 91.7 0.097 86.3 66.7 0.086
(0.0-100.0) (33.0-100.0) (33.0-100.0) (0.0-100.0)
Mental Health 69.5 82 0.047 79.5 75.1 0.498
(36.0-96.0) (72.0-88.0) (40.0-100.0) (48.0-95.0)
QLQ-C30 transf. scores
Global health status in total 68.2 87.5 0.012 64.1 67.2 0.218
(16.7-100.0) (75.0-100.0) (33.3-100.0) (0.0-100.0)
Functioning in total 90.8 95 0.13 83 88.6 0.085
(70.7-100.0) (86.7-100.0) (49.3-100.0) (51.7-100.0)
Physical functioning 95.8 98.3 0.106 89 95 0.22
(87.0-100.0) (93.0-100.0) (67.0-100.0) (87.0-100.0)
Role functioning 86.4 97.2 0.03 75.5 87.5 0.969
(67.0-100.0) (83.0-100.0) (33.0-100.0) (33.0-100.0)
Emotional functioning 93.2 92.1 0.795 90.1 85.4 0.456
(66.7-100.0) (66.7-100.0) (66.7-100.0) (58.3-100.0)
Cognitive functioning 89.4 94.4 0.344 79.2 86.5 0.132
(50.0-100.0) (83.3-100.0) (16.7-100.0) (66.7-100.0)
Social functioning 89.4 93.1 0.558 80.2 88.5 0.851
(67.0-100.0) (67.0-100.0) (17.0-100.0) (0.0-100.0)
Symptoms. problems in total 12.2 6 0.047 20.7 18.7 0.285
(3.7-25.9) (0.0-16.7) (1.2-53.2) (0.0-50.6)
Fatigue 18.7 17.6 0.859 36.3 28.5 0.086
(0.0-33.0) (0.0-33.0) (0.0-78.0) (0.0-89.0)
Nausea and vomiting 7.6 0 0.075 15.7 9.4 0.498
(0.0-33.3) (0.0-83.3) (0.0-16.7)
Pain 16.7 2.8 0.009 29.4 20.8 0.819
(0.0-33.0) (0.0-17.0) (0.0-83.0) (0.0-67.0)
Dyspnea 12.1 11.1 0.879 19.6 15.6 0.203
(0.0-33.0) (0.0-33.0) (0.0-67.0) (0.0-67.0)
Insomnia 27.3 8.3 0.018 27.5 37.8 0.084
(0.0-66.7) (0.0-33.3) (0.0-100.0) (0.0-100.0)
Appetite loss 0 0 NA 12.5 6.3 0.077
(0.0-67.0) (0.0-33.0)
Constipation 9.1 0 0.164 5.9 4.2 0.528
(0.0-67.0) (0.0-67.0) (0.0-33.0)
Diarrhea 12.1 13.9 0.8 13.3 29.2 0.378
(0.0-33.3) (0.0-33.3) (0.0-66.7) (0.0-100.0)
Financial difficulties 6.1 0 0.143 18.8 16.7 0.542
(0.0-33.0) (0.0-100.0) (0.0-100.0)
1ANCOVA model with patients groups as factor and age as continuous covariate was adopted for the analysis
2Score values expressed as arithmetic mean with min-max values (in parentheses)
3Statistically significant results are given in bold (p<0.05)
Table 3: Comparison of SF-36/QLQ-C30 scores between group A-patients treated with Imatinib for 15 months (median) and group B-patients treated with Imatinib for 50 months (median) adjusted for age in the ANCOVA model1.